CERo Therapeutics Holdings マネジメント

マネジメント基準チェック /04

CERo Therapeutics Holdingsの CEO はChris Ehrlichで、 Sep2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の3.86%を直接所有しており、その価値は$ 851.92K 。経営陣と取締役会の平均在任期間はそれぞれ0.1年と0.8年です。

主要情報

Chris Ehrlich

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	3.9%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO（最高経営責任者

Chris Ehrlich (54 yo)

less than a year

在職期間

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christopher Ehrlich	CEO & Chair	less than a year	データなし	3.86% $ 851.9k
Brian Atwood	President & Director	no data	データなし	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	データなし	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	データなし	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	データなし	0% $ 0

0.08yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: CEROの経営陣は経験豊富とはみなされません ( 0.1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Christopher Ehrlich	CEO & Chair	less than a year	データなし	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	データなし	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	データなし	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	データなし	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	データなし	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	データなし	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	データなし	データなし
Adrian Bot	Scientific Advisor	no data	データなし	データなし
Antonio Lanzavecchia	Scientific Advisor	no data	データなし	データなし
Rafi Ahmed	Scientific Advisor	no data	データなし	データなし
Michael Byrnes	Independent Director	less than a year	データなし	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	データなし	0% $ 0

0.8yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: CEROの取締役会は経験豊富ではない ( 0.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

CERo Therapeutics Holdings マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04